Related Experiment Video

Updated: Aug 10, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations

Gregg C Fonarow1

  • 1Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Reviews in Cardiovascular Medicine
|March 15, 2006
PubMed

Insights

Beta-blockers are crucial for reducing mortality and reinfarction after myocardial infarction (MI). This article details their practical use, guiding clinicians on optimal beta-blocker selection and administration post-MI.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are proven to reduce mortality and reinfarction risk post-myocardial infarction (MI).
  • Current guidelines strongly recommend indefinite beta-blocker therapy for post-MI patients unless contraindicated.
  • Despite evidence, beta-blocker prescription rates and adherence remain suboptimal.

Purpose of the Study:

  • To discuss the practical implementation of beta-blocker therapy in post-myocardial infarction (MI) patients.
  • To provide rationale for selecting specific beta-blockers based on evidence.
  • To present protocols for initiating or switching to evidence-based beta-blocker therapies.

Main Methods:

  • Review of current clinical guidelines and evidence-based research on beta-blocker use post-MI.
  • Discussion of practical considerations for beta-blocker initiation and titration.
  • Outline of strategies for managing patients not receiving or inadequately treated with beta-blockers.

Main Results:

  • Beta-blockers significantly decrease mortality and reinfarction risk in both acute and long-term post-MI periods.
  • Non-adherence and suboptimal prescribing of beta-blockers persist despite strong recommendations.
  • Specific protocols can improve the effective use of evidence-based beta-blockers.

Conclusions:

  • Optimal use of beta-blockers post-MI is essential for improving patient outcomes.
  • Addressing barriers to beta-blocker prescription and adherence is critical.
  • Standardized protocols can enhance the application of guideline-directed beta-blocker therapy.

More Related Videos

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...